Axsome to Present Results of SHARP Study at Psych Congress

Axsome is set to present new data on Sunosi (solriamfetol) in patients with excessive daytime sleepiness (EDS) due to narcolepsy and OSA.

Related Keywords

Germany ,David Gozal ,Johannes Gutenberg ,Craig Chepke ,Hans Van Dongen ,Washington State University ,Axsome Therapeutics Inc ,Medicine Center ,Psych Congress ,University Of Missouri ,Cecilia Brain ,Cognitive Function ,Obstructive Sleep Apnea ,Washington State ,Solriamfetol Improves Cognitive Performance ,Preclinical Models ,Sleep Apnea ,Randomized Placebo Controlled Study ,Sleep Apnea Participants ,Excessive Sleepiness ,Effect Sizes ,Numbers Needed ,Follow Up Experience ,Patients With ,Yaroslav Winter ,Mainz Comprehensive Epilepsy ,Sleep Medicine Center ,Johannes Gutenberg University ,